Edwards Presents (TRISCEND) Study Results of EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation at PCR 2022

Shots:

The company reported the 1yr. results from the (TRISCEND) study evaluating EVOQUE  transcatheter tricuspid valve replacement system in 176 patients with tricuspid regurgitation. Enrolled patients had symptomatic mod. or greater functional or degenerative TR, despite optimal medical therapy
The results showed a favorable safety, efficacy & QoL outcome, 90.1% high survival and high freedom from HF hospitalization at 88.4%; significant and sustained TR reduction with 97.6% with mild or trace TR, 93% of patients in NYHA Class I or II vs 26% at baseline and a 26-point increase in KCCQ score
The system demonstrated a persistent improvement in symptom status and low rates of mortality & HF hospitalizations @1yr. follow-up

Ref: PRNewswire | Image: Edwards